Covid Treatment Update

Changes to the COVID-19 protocols for triage and treatment:

Covid Treatment Update: Because of the sudden rise in new coronavirus infections and the Omicron type, the organization changed the way it triages and treats COVID-19. Except for medical college hospitals, government hospitals, and hospitals specifically designated for COVID-19, all healthcare facilities should follow the committee’s updated recommendations for first triaging and managing COVID-19 patients.

In a letter to all district collectors, the Greater Chennai Corporation (GCC), district-level health teams, deans, and city health officers, the Health Secretary said that the updated protocol, which focuses on home isolation for fully immunized, asymptomatic, and other people, has just been released.

After talking to top health officials, clinical experts, and the directors of public health and preventive medicine, medical education, and medical and rural health services, the procedure was changed. This was done so that very clear instructions could be given about home isolation and admission to COVID-19 care centers, COVID-19 health centers, and hospitals.

If patients couldn’t stay at home alone, they could be sent to CCCs. People older than 60, women who are pregnant, or women who are nursing should be sent to COVID-19 hospitals. People with a history of severe COVID-19 or death in their family should be sent to a higher level of care. People who weren’t immunized and had more than one disease would be admitted to CCC and watched for at least five days, no matter what their symptoms were. People who didn’t have more than one disease and didn’t have any symptoms, on the other hand, would be watched at home.

Here are the most recent changes to the treatment of COVID-19:

During a public health emergency, like COVID-19, the FDA can give out emergency use authorizations (EUAs) to make new medicines and medical products available before they have been fully approved by the FDA. There are now a lot of medicines for treating COVID-19 with an EUA, both inside and outside of the hospital.

On the other hand, the FDA changes the recommended dosage for these medicines from time to time. Updates are made as medical professionals learn more about how well these changes work, especially when it comes to new virus strains. Since these changes happen so often, it may be hard to keep up with the latest information and ideas.

Pfizer will ask the FDA to give full approval to Paxlovid for people who have a high chance of getting severe COVID-19:

In the United States, Paxlovid is currently approved for use in emergency situations. However, Pfizer has said that it plans to file for full FDA approval of Paxlovid for patients who are at high risk of getting severe COVID-19. Before this release, Pfizer did a number of studies to see how safe and effective Paxlovid was. Researchers have looked into how well Paxlovid works for COVID-19 patients who have a low, moderate, or high chance of getting sick.

A new study that looked at people with an average chance of getting a serious illness found mixed results. Even though the main goal of the trial wasn’t met, Paxloxid seemed to make it less likely that people would end up in the hospital or die compared to a placebo (a pill with no medication in it).

Pfizer will use this information to support the application for Paxlovid to treat COVID-19 in people who are at a high risk of getting a serious disease. It has no plans to ask the FDA for full approval for people who have an average chance of getting sick.

Remdesivir (Veklury):

Remdesivir (Veklury) is an antiviral drug that is given through an IV. It works by stopping a protein enzyme that is needed for viruses to make more copies of themselves.

In May 2020, the FDA approved Remdesivir for the first time to be used in hospitals. It will be fully approved by the FDA for people 12 and older in October 2020. People of all ages could use it outside of a hospital in January 2022. Also, it got final approval in April 2022 for a small group of children who were at least 28 days old.

The NIH currently recommends Remdesivir as a backup option for some adults over the age of 12 who do not need to be hospitalized but have mild to moderate COVID-19 and are at a high risk of getting a serious illness. This means that Paxlovid is recommended, but remdesivir can be used instead if Paxlovid can’t be found or gotten. Also, this use is legal for kids who are at least 28 days old and weigh at least 3 kg (about 7 pounds). Remdesivir could also be used for hospital patients who need more oxygen.

Covid Treatment Update: Remdesivir is given by injecting it into a vein. People who are not in the hospital get infusions every day for three days. As soon as the diagnosis is made, seven days after the first signs, treatment should begin. Most people who are in the hospital get infusions every day for 5 to 10 days.

Leave a Reply

Your email address will not be published. Required fields are marked *